Who
Beth Hecht
Officer
Company insider
Files Form 4 as: Officer, Xeris Biopharma Holdings; Director, Iterum Therapeutics; Officer, Xeris Pharmaceuticals; Director, Aytu BioPharma; Director, Neos Therapeutics.
In numbers
- Trades disclosed
- 96
- Buys
- 3
- Sells
- 13
- Bought
- $49K
- Sold
- $2.7M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 1 Oct 2015
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $157K16,666 at $9.41 | filing |
| 1 Sep 2026filed 1 Sep 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $141K16,666 at $8.49 | filing |
| 1 Sep 2026filed 1 Sep 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $141K16,666 at $8.49 | filing |
| 3 Aug 2026filed 4 Aug 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $134K16,666 at $8.01 | filing |
| 3 Aug 2026filed 4 Aug 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $133K16,666 at $8.01 | filing |
| 1 Jul 2026filed 2 Jul 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $134K16,666 at $8.03 | filing |
| 1 Jul 2026filed 2 Jul 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $134K16,666 at $8.03 | filing |
| 1 Jun 2026filed 2 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $101K16,667 at $6.06 | filing |
| 1 Jun 2026filed 2 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $101K16,667 at $6.06 | filing |
| 1 May 2026filed 1 May 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $104K16,667 at $6.23 | filing |
| 1 May 2026filed 1 May 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $104K16,667 at $6.23 | filing |
| 1 Apr 2026filed 3 Apr 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $100K16,667 at $5.99 | filing |
| 1 Apr 2026filed 3 Apr 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $100K16,667 at $5.99 | filing |
| 2 Mar 2026filed 4 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $103K16,567 at $6.24 | filing |
| 2 Mar 2026filed 4 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $706100 at $7.06 | filing |
| 2 Mar 2026filed 4 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $103K16,567 at $6.24 | filing |
| 2 Mar 2026filed 4 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $706100 at $7.06 | filing |
| 2 Feb 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $124K16,667 at $7.45 | filing |
| 2 Feb 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $124K16,667 at $7.45 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $724K98,375 at $7.36 | filing |
News
Financial Survey: Iterum Therapeutics (NASDAQ:ITRM) versus Xeris Biopharma (NASDAQ:XERS)XERS · tickerreport.com · 22 Oct 2026Reviewing MediciNova (NASDAQ:MNOV) & Xeris Biopharma (NASDAQ:XERS)XERS · dailypolitical.com · 22 Oct 2026Critical Contrast: Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS)XERS · tickerreport.com · 21 Oct 2026
0 headlines in the last 90 days name Beth Hecht; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.